These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 4447919)

  • 1. Effects of cis-diamminedichloroplatinum (NSC-119875) on hearing function in man.
    Piel IJ; Meyer D; Perlia CP; Wolfe VI
    Cancer Chemother Rep; 1974; 58(6):871-5. PubMed ID: 4447919
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical trials of cis-diamminedichloroplatinum (NSC-119875).
    Lippman AJ; Helson C; Helson L; Krakoff IH
    Cancer Chemother Rep; 1973 Apr; 57(2):191-200. PubMed ID: 4126381
    [No Abstract]   [Full Text] [Related]  

  • 3. Preliminary clinical experience with cis-diamminedichloroplatinum (II) (NSC 119875, CACP).
    Rossof AH; Slayton RE; Perlia CP
    Cancer; 1972 Dec; 30(6):1451-6. PubMed ID: 4641756
    [No Abstract]   [Full Text] [Related]  

  • 4. Patterns of hearing loss resulting from cis-platinum therapy.
    Blakley BW; Myers SF
    Otolaryngol Head Neck Surg; 1993 Sep; 109(3 Pt 1):385-91. PubMed ID: 8414553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of cis-diamminedichloroplatinum (NSC-119875) in advanced carcinoma of the large bowel.
    Kovach JS; Moertel CG; Schutt AJ; Reitemeier RG; Hahn RG
    Cancer Chemother Rep; 1973; 57(3):357-9. PubMed ID: 4584486
    [No Abstract]   [Full Text] [Related]  

  • 6. cis-Platinum ototoxicity.
    Helson L; Okonkwo E; Anton L; Cvitkovic E
    Clin Toxicol; 1978; 13(4):469-78. PubMed ID: 747905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of toxic effects of cis-diamminedichloroplatinum (NSC-119875)--phase I clinical study.
    Talley RW; O'Bryan RM; Gutterman JU; Brownlee RW; McCredie KB
    Cancer Chemother Rep; 1973; 57(4):465-71. PubMed ID: 4762440
    [No Abstract]   [Full Text] [Related]  

  • 8. Hearing loss--risk factor for cisplatin ototoxicity? Observations.
    Durrant JD; Rodgers G; Myers EN; Johnson JT
    Am J Otol; 1990 Sep; 11(5):375-7. PubMed ID: 2240186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. cis-platinum ototoxicity in children.
    Pasic TR; Dobie RA
    Laryngoscope; 1991 Sep; 101(9):985-91. PubMed ID: 1886448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin.
    Riedemann L; Lanvers C; Deuster D; Peters U; Boos J; Jürgens H; am Zehnhoff-Dinnesen A
    Pharmacogenomics J; 2008 Feb; 8(1):23-8. PubMed ID: 17457342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity of cis-diamminedichloroplatinum II given in a two-hour outpatient regimen of diuresis and hydration.
    Vogl SE; Zaravinos T; Kaplan BH
    Cancer; 1980 Jan; 45(1):11-5. PubMed ID: 7188679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polycythemia vera in the childbearing age.
    Harris RE; Conrad FG
    Arch Intern Med; 1967 Dec; 120(6):697-700. PubMed ID: 6058404
    [No Abstract]   [Full Text] [Related]  

  • 13. Cis-diamminedichloroplatinum (II). A new anticancer drug.
    Rozencweig M; von Hoff DD; Slavik M; Muggia FM
    Ann Intern Med; 1977 Jun; 86(6):803-12. PubMed ID: 326117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Early detection of cisplatin-induced ototoxicity using evoked otoacoustic emissions].
    Plinkert PK; Kröber S
    Laryngorhinootologie; 1991 Sep; 70(9):457-62. PubMed ID: 1930486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of leukemias in man by L-asparaginase.
    Oettgen HF; Old LJ; Boyse EA; Campbell HA; Philips FS; Clarkson BD; Tallal L; Leeper RD; Schwartz MK; Kim JH
    Cancer Res; 1967 Dec; 27(12):2619-31. PubMed ID: 5237354
    [No Abstract]   [Full Text] [Related]  

  • 16. High-dose cisplatin treatment: hearing loss and plasma concentrations.
    Laurell G; Jungnelius U
    Laryngoscope; 1990 Jul; 100(7):724-34. PubMed ID: 2362532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [First therapeutic experience with cis-platinum(II)diamindichloride (NSC 119875) in metastasizing ovarian and testicular carcinoma].
    Cavalli F; Sonntag RW; Ryssel HJ; Tschopp L; Brunner KW
    Schweiz Med Wochenschr; 1976 May; 106(22):754-7. PubMed ID: 996494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adriamycin (NSC-123127) in combination with cyclophosphamide (NSC-26271): a phase I and II evaluation.
    Muggia FM; Perloff M; Chia GA; Reed LJ; Escher GC
    Cancer Chemother Rep; 1974; 58(6):919-26. PubMed ID: 4614899
    [No Abstract]   [Full Text] [Related]  

  • 19. Preliminary clinical trial of 1-(2-chlorethyl)-3-(4-methylcyclohexyl)-1 nitrosourea (NSC-95411) (MeCCNU) in human neoplasms.
    Gailani S; Kutcher J
    J Med; 1973; 4(4):209-18. PubMed ID: 4520348
    [No Abstract]   [Full Text] [Related]  

  • 20. Nephrotoxic potential of cis-diamminedichloroplatinum and four analogs in male Fischer 344 rats.
    Levine BS; Henry MC; Port CD; Richter WR; Urbanek MA
    J Natl Cancer Inst; 1981 Jul; 67(1):201-6. PubMed ID: 6942191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.